Gapping down
In reaction to disappointing earnings/guidance: NEON -16.3%, (issues guidance; also prices its underwritten public offering of 3.2 mln shares of common stock at $1.90/share), YUM -15.4%, NUS -14.5%, MON -3.5%, RPM -3.1%, PAH -2.9%, ADBE -2.2%
Select pharma related names showing weakness: AZN -1.5%, TEVA -1.5%, SNY -1.4%, SHPG -1%
Other news: AXPW -55% (announced that the exclusivity period under its Binding Letter of Intent with LCB International expired; LCB has indicated an unwillingness to move forward with any deal structure that contemplates anything further than a technology license), ADXS -19.5% (reports Clinical Hold of Investigational Agent Axalimogene Filolisbac; expects hold to be resolved expeditiously and without significant interruption to the HPV clinical development program), CTRV -13.5% (announces offering of common stock and warrants to purchase common stock for an undisclosed amount ), RSPP -3.4% (commences an underwritten public offering of 6 mln shares of its common stock), SUNE -2.8% (cont volatility pre-mkt), AVXL-2.1% (announces a 1-for-4 reverse stock split in preparation for Nasdaq uplisting), MCD -1.4% (following YUM results), PBF -0.5% (prices public offering of 10 mln shares of class A common stock at $31 per share)
Analyst comments: GPRO -2.3% (target lowered to $35 from $62 at Morgan Stanley), TSLA -1.8% (downgraded to Neutral from Outperform at Robert W. Baird), JCP -1.8% (initiated with Sell at Citigroup)
In reaction to disappointing earnings/guidance: NEON -16.3%, (issues guidance; also prices its underwritten public offering of 3.2 mln shares of common stock at $1.90/share), YUM -15.4%, NUS -14.5%, MON -3.5%, RPM -3.1%, PAH -2.9%, ADBE -2.2%
Select pharma related names showing weakness: AZN -1.5%, TEVA -1.5%, SNY -1.4%, SHPG -1%
Other news: AXPW -55% (announced that the exclusivity period under its Binding Letter of Intent with LCB International expired; LCB has indicated an unwillingness to move forward with any deal structure that contemplates anything further than a technology license), ADXS -19.5% (reports Clinical Hold of Investigational Agent Axalimogene Filolisbac; expects hold to be resolved expeditiously and without significant interruption to the HPV clinical development program), CTRV -13.5% (announces offering of common stock and warrants to purchase common stock for an undisclosed amount ), RSPP -3.4% (commences an underwritten public offering of 6 mln shares of its common stock), SUNE -2.8% (cont volatility pre-mkt), AVXL-2.1% (announces a 1-for-4 reverse stock split in preparation for Nasdaq uplisting), MCD -1.4% (following YUM results), PBF -0.5% (prices public offering of 10 mln shares of class A common stock at $31 per share)
Analyst comments: GPRO -2.3% (target lowered to $35 from $62 at Morgan Stanley), TSLA -1.8% (downgraded to Neutral from Outperform at Robert W. Baird), JCP -1.8% (initiated with Sell at Citigroup)